18/6/2024, 11:11:02 am

Zydus Life’s unit at Pharmez SEZ classified as OAI by USFDA

Zydus Lifesciences' injectable manufacturing plant in India received an "Official Action Indicated" classification from the USFDA following an inspection. Despite this, the company reported a four-fold increase in net profit to ₹1,182 Crore for Q4 2024, driven by increased sales. Revenue from operations rose to ₹19,547 Crore, and the company declared a combined net profit of ₹3,859 Crore.